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1.1 The Placebo Effect: a Neurobiological Phenomenon 
Mounting evidence from different methodological approaches indicate that the placebo 
effect is a ´true´ quantifiable neurobiological phenomenon (Benedetti, Mayberg, Wager, 
Stohler, & Zubieta, 2005; Meissner et al., 2011; Price, Finniss, & Benedetti, 2008). Specifically, 
it reflects a measurable health response that is in fact triggered by a sham therapy, which con-
tains no pharmacological ingredient and is not inherently designed to give rise to any specific 
medical effects (Price et al., 2008). It is generally assumed that the placebo effect begins by a 
modulation of the mind (Benedetti, 2010; Benedetti, Carlino, & Pollo, 2011; Pollo, Carlino, & 
Benedetti, 2008), which in turn can activate a cascade of measurable neurobiological changes 
similar to those activated by real drugs.  
For example, in placebo analgesia (i.e. pain reduction induced by placebos), it has been 
shown that the release of endogenous opiates was associated with the subjective placebo re-
sponse (for a review on placebo analgesia, see Colloca, Klinger, Flor, & Bingel, 2013). Notably, 
it was not possible to create the same placebo response when the endogenous opiates were 
blocked by naloxone (Benedetti, 1996). In other words, the placebo effect on pain required its 
biological correlate – endogenous opiates released from the central nervous system (CNS) – to 
act. Another study by Hunter and colleagues revealed that the placebo effect plays a key role in 
the actual treatment of depression. In patients with severe depression, prefrontal cortex (PFC) 
activity was measured prior to the beginning of a treatment with antidepressants (i.e. during the 
placebo lead-in phase). Nineteen percent of the benefit (reduction on Hamilton depression 
scale) in these medication-treated subjects could be predicted by a decrease in PFC activity 
during the placebo-lead in phase (Hunter, Leuchter, Morgan, & Cook, 2006). The authors sug-
gested that the altered PFC activity was induced through positive associations with the admin-




the ‘influence of the psychosocial context of a treatment’ and are considered to be a crucial 
mechanism of the placebo effect (Benedetti, 2006). It has also been suggested that the placebo 
effect is modulated via reward-specific mechanisms (de la Fuente-Fernández, Lidstone, & 
Stoessl, 2006), such as the release of dopamine in the striatum in Parkinson´s disease (de la 
Fuente-Fernández, Ruth, Sossi, Schulzer, Calne, & Stoessl, 2001). 
These examples elucidate that the placebo effect can play a significant role in health care 
and transform its previous label of ‘pure imagination’ into a more accurate label as a true quan-
tifiable neurobiological phenomenon. On top of that, placebo research sheds new light on mind-
body interactions by connecting subjective experience to neurobiological changes (Colloca & 
Benedetti, 2005). However, despite the growing evidence pointing to the validity of the placebo 
effect, more substantial knowledge is needed before applying the placebo effect to medicine 
(Price et al., 2008). For example, little is known about the mechanism of the placebo effect in 
nausea, even though it is a commonly occurring clinical condition known to be sensitive to 
placebo interventions (Quinn & Colagiuri, 2015). To fill this gap, the present study investigates 
the placebo effect in a nausea model, specifically its underlying cognitive mechanism and its 
linkage to expectation and stress.  
1.2 Placebo Effect in Nausea 
The placebo effect plays a crucial role in the treatment of acute nausea and has been 
described in chemotherapy patients (Enblom et al., 2012), pregnant women (Borrelli, Capasso, 
Aviello, Pittler, & Izzo, 2005), and healthy populations. In these populations, nausea has been 
shown to be alleviated by placebo interventions in comparison with a no-treatment control 
group, but with varying level of evidence (Quinn & Colagiuri, 2015). A competitive distinction 
between ‘verbal instructions’ and ‘conditioning’ has been proposed in the past (Peck & Cole-
man, 1991; Voudouris, Peck, & Coleman, 1990), however others (Quinn & Colagiuri, 2015; 
Stewart-Williams & Podd, 2004) argue that both processes can induce placebo effects and 
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should be integrated. Broadly defined, instruction based interventions include conscious ma-
nipulations, e.g. ‘this pill was shown to positively affect your stomach and therefore will pre-
vent you from experiencing nausea’. In contrast, the conditioned placebo effect more likely 
comprises the hidden actions (e.g. context factors such as the form of a drug, Wickramasekera, 
1980) and has been shown to act even without conscious perception of the conditioned stimuli 
(e.g. in the domain of pain, Jensen et al., 2012). In fact, it seems that both interventions trigger 
expectancy towards a positive treatment outcome, independently of whether this happens con-
sciously or unconsciously (Stewart-Williams & Podd, 2004).  
In a study that integrated both concepts, a lemon flavored water drink, presumed to be an 
effective antiemetic (placebo group) or pure water without instruction (control group) was ad-
ministered prior to a nauseating stimulus (Horing et al., 2013). The nauseating stimulus was 
performed on three consecutive days, and had in fact been surreptitiously decreased following 
the placebo treatment at day two relative to each participant’s first session. This was important 
in order to induce the conditioning effect at session three, in which the nauseating stimulus was 
returned to the initial high level after another placebo treatment was applied. In this session, the 
placebo subjects showed twice the magnitude of symptom reduction compared to the control 
group. However, similar placebo effects have also been observed at day two, where only the 
placebo instruction was applied. Hence, the authors suggested that the placebo instruction alone 
was as effective as in combination with conditioning. 
In another study by Quinn and colleagues (2015), 56 participants received either the in-
struction that a sham treatment – a peppermint essence vapor - would reduce nausea (instruction 
and conditioning) or no information (only conditioning). The conditioning was induced by pair-
ing the sham treatment with a surreptitious decrease in the severity of nausea induction versus 
no prior pairing (control group). In a final session, peppermint essence vapor induced equal 




received conditioning and those who received both. These results confirm the study by Horing 
and colleagues (2013) and further suggest that placebo effects in nausea can be induced to a 
similar degree through conditioning, instruction or their combination.  
Based on these results, Quinn and colleagues (2015) proposed three key factors to ensure 
powerful placebo effects in nausea, namely: a) high initial expectations for experiencing nausea 
(Horing et al., 2013; Müller, Remus, Hoffmann, Tschöp, & Meissner, 2016), b) reasonable and 
convincing expectancy manipulations (i.e. verbal instructions of the placebo intervention), and 
c) verbal instructions should be followed by a placebo intervention (e.g. sham acupuncture: 
Müller et al., 2016 or placebo pills: Weimer et al., 2012).  
Recently, a study by Müller and colleagues (2016) supported these claims by implement-
ing the key factors and obtaining powerful placebo effects in nausea in female participants 
(partial Ƞ2 = .71): first, high initial expectations of experiencing nausea were induced by ex-
posing participants to the nauseating stimulus prior to the main experiment and including only 
those who experienced moderate nausea. Second, the placebo intervention included a reasona-
ble instruction in the form of a positive verbal suggestion that the intervention would improve 
nausea. Third, instructions were followed by a sham acupuncture point stimulation, which has 
been indicated as the most effective placebo intervention (Linde, Niemann, Schneider, & Meiss-
ner, 2010; Meissner et al., 2013).  
In sum, these findings show that the placebo effect can be systematically induced and 
studied in nausea. Despite the fact that placebo interventions can powerfully reduce nausea, 
little is known about the exact underlying mechanisms. However, the bodily and cortical mech-
anisms of nausea have been studied more thoroughly, providing a reliable basis to investigate 
the placebo mechanisms in more detail.   
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1.3 Nausea  
Nausea is a widespread and highly individual condition, which ranges from relatively 
harmless during motion in approximately 30% of the car drivers (Turner & Griffin, 1999) to 
intolerable in 25% of cancer patients receiving chemo-therapy (Morrow, Hickok, DuBeshter, 
& Lipshultz, 1999) and in 52% of pregnant women (Gadsby, Barnie-Adshead, & Jagger, 1993). 
Its signs and symptoms include physical (e.g. sweating or vomiting), emotional (e.g. stress), 
cortical (e.g. changes in brain activity) and gastrointestinal (e.g. stomach ache) afflictions (Lev-
ine, 2017).  
1.3.1 Motion Sickness Induced Nausea 
One appropriate way to experimentally study nausea is to induce nausea through motion. 
Motion sickness can be induced by means of a vection drum, which works through illusory self-
motion (Hettinger, Schmidt-Daly, Jones, & Keshavarz, 2014). Vection drums usually consist of 
black and white stripes moving constantly from left to right (Reason & Brand, 1975). Moving 
dots have also been used to induce motion sickness (Klosterhalfen, Muth, Kellermann, Meiss-
ner, & Enck, 2008). These types of stimuli recreate sensory conflicts similar to those encoun-
tered while driving a car or piloting an airplane. As a result, sensory organs report conflicting 
spatial and moving information due to difference in expected and the sensed motion cues. This 
theory is called the sensory rearrangement theory (Reason & Brand, 1975), which was later 
refined to the subjective vertical conflict theory (Bles, Bos, de Graaf, Groen, & Wertheim, 1998; 
de Graaf, Bles, & Bos, 1998). The latter implies that motion sickness can only be induced when 
the sensory conflict is between the expected internal calculated vertical and the perceived ver-
tical. It follows then that the vection drums usually work with vertical illusions. Both theories 
assume that such a sensory mismatch in susceptible subjects (which varies greatly) leads to 
neural mismatching (error signaling) in the brain-stem causing several symptoms, predomi-




Bodily changes of nausea in the context of motion sickness are well studied and have 
been suggested to act in a bidirectional network composed of mechanisms within the autonomic 
nervous system (ANS), the central nervous system (CNS), and the endocrine system (Singh, 
Yoon, & Kuo, 2016). Recently, this was evidenced by an fMRI study (Farmer et al., 2015), in 
which nauseated subjects were shown to have gastric dysrhythmia, blunted levels of plasma 
ghrelin as well as increased activation in the inferior frontal and the anterior cingulate cortex 
(ACC). Nevertheless, little is known about the psychosocial influences on nausea in the context 
of motion sickness, such as stress.  
1.3.2 Nausea and Stress 
Notably, a wealth of research has shown that psychosocial aspects play a key role in nau-
sea (Levine, 2017). For example, nausea is often accompanied by elevated stress levels. ANS 
response to stress shows robust similarities with the ANS pattern in nauseated patients in the 
context of motion sickness (Stern & Koch, 1996), chemotherapy (Gianaros, Stern, Morrow, & 
Hickok, 2001), and pregnancy (Koch et al., 1990; Levine, 2017). The ANS acts via two 
branches to direct bodily reactions, namely: (a) the parasympathetic nervous system (PNS) and 
(b) the sympathetic nervous system (SNS). The PNS regulates bodily activity at rest, such as 
digestion. In contrast, the SNS is important for the so called ‘fight-or-flight’ reaction (McCarty, 
2007). At times of stress, the ANS is indexed by increased SNS and decreased PNS activity to 
mobilize energy resources (McEwen, 1998). The experience of nausea is indexed by similar 
ANS patterns (Stern & Koch, 1996). The order in which stress and nausea act together (whether 
nausea causes stress or vice versa) is not yet clear. It has however, been shown that acute stress 
can evoke abnormal gastric myoelectrical activity (Muth, Koch, Stern, & Thayer, 1999). It is 
possible that at times of stress, there is little energy left for digestion and the gastrointestinal 
system may be suppressed, which in turn may trigger nausea (Gianaros, Quigley, et al., 2001).  
Neurophysiological Correlates of the Placebo Effect in Nausea 
12 
 
The interplay between SNS and PNS is mainly navigated via three brain regions, the hip-
pocampus, amygdala, and PFC (taking into account that stress leads to far more intricate bio-
behavioral changes; McEwen et al., 2015). Together, they regulate the release of stress related 
hormones via the hypothalamic-pituitary-adrenal (HPA) axis in the ANS, such as cortisol or 
amylase.  
1.3.3 Nausea and Salivary Enzyme Alpha-Amylase 
Though alpha-amylase has been indicated to play a crucial role in digestion, little is 
known about the link between alpha-amylase and nausea (Layer, Zinsmeister, & DiMagno, 
1986). However, based on the fact that acute nausea is accompanied by altered stomach activity, 
thus altered digestive tract activity (Farmer, 2015), it follows that alpha-amylase may be directly 
involved in the development of acute nausea.    
Additionally, alpha-amylase was shown to indicate increased stress levels (Nater et al., 
2006). For example, one study measured changes in alpha-amylase, salivary cortisol and heart 
rate in 30 healthy men following Trier Social Stress Test (TSST). All three measures signifi-
cantly increased. An investigation of the associations between the measures revealed that while 
sympathetic cardiovascular tone was positively correlated with alpha-amylase, changes in cor-
tisol levels were not significantly associated with changes in alpha amylase (r < 0.25). There-
fore, alpha-amylase was included in the current study as a potential stress-related mediator in 
addition to cortisol and to index altered SNS activity (Nater & Rohleder, 2009) underlying the 
placebo effect in nausea.  
1.3.4 Nausea and Cortisol 
Nausea in the context of motion sickness has been shown to be accompanied by elevated 
cortisol levels (Xu et al., 1993). On the other hand, high levels of cortisol measured prior to the 




Enck, Muth, Kellermann, & Klosterhalfen, 2009). In general, the hormone cortisol plays a cru-
cial role in the HPA-axis. Released from the adrenal cortex, it can redistribute energy via neg-
ative feedback loops at mineralocorticoid and glucocorticoid receptors, primarily found in the 
hypothalamus. For example, cortisol can nourish muscles with energy in form of increased glu-
cose levels (Gonzalez-Bono, Rohleder, Hellhammer, Salvador, & Kirschbaum, 2002) or re-
duces gastro-intestinal activity (Bhatia & Tandon, 2005). It also closely interacts with certain 
brain areas, such as the PFC (Dedovic, D’Aguiar, & Pruessner, 2009). However, the exact re-
lationship between PFC and cortisol has not yet been clarified and seems to differ between 
females and males (Wang et al., 2007). In summary, cortisol was shown to be relevant in nausea, 
though its exact function is still unclear. Changes in cortisol levels may index, among other 
components, the magnitude of the placebo effect in nausea.  
1.3.5 Nausea and the Central Nervous System 
Regarding the central nervous system (CNS), several studies revealed electroencephalog-
raphy (EEG) frequencies of the fast Fourier transformed (FFT) spectrum to be altered during 
acute nausea. FFT transforms data from the time domain into the frequency domain and shows 
the extent to which each frequency band are represented within the EEG recordings (Cooley & 
Tukey, 1965). The frequency bands can be defined according to the spectrum of interest. In the 
investigation of nausea, frequency bands are usually defined between ‘0’ and ‘30’ hertz (Hz). 
For example, Hu and colleagues (1999) investigated theta (‘0’ – ‘4’ Hz), delta (‘4.1’-‘8’ Hz), 
alpha (‘8.1’-‘13’ Hz), beta I (13.1-20), and beta II (’13.1’ - ‘30’ Hz) bands and showed that the 
percentage of delta power (compared to the whole spectrum of ‘0’ to ‘30’ Hz) in the central 
electrodes C3 and C4 was increased during acute nausea. Additionally, brain imaging programs 
such as exact low resolution brain electromagnetic tomography algorithm (eLORETA; Pascual-
Marqui, 2002; Pascual-Marqui, 2007) have allowed researchers to localize these nausea related 
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EEG changes. For example, parietal, motor, and occipital areas were revealed to exhibit signif-
icant nausea related EEG changes (Ko, Wei, Jung, & Lin, 2011). Specifically, parietal and motor 
components exhibited alpha power suppression and occipital components elevated power of 
theta and delta bands, measured during acute nausea (Chelen, Kabrisky, & Rogers, 1993; Chen 
et al., 2010). Furthermore, in an fMRI study that was based on 28 female participants, nausea 
was accompanied by changes in the insular, ACC, orbitofrontal, somatosensory, and prefrontal 
cortices (Napadow et al., 2013). In particular, the authors observed a strong correlation between 
anterior insula (thought to be involved in emotion regulation) and ACC activation and suggested 
a closer linkage between these regions within the brain circuitry underlying nausea. These find-
ings align perfectly with fMRI findings by Farmer and colleagues (2015) in which anterior 
cingulate as well as the frontal cortex were identified as key cortical components in nausea.   
In summary, these studies clearly show that changes in the CNS are related to the subjec-
tive experience of nausea and that EEG reflects a potential measurement to investigate, in more 
detail, psychosocial top-down modulations, such as anticipatory nausea.  
1.4 Expectation and the Treatment of Nausea 
While some medical treatments of nausea lead to remission of symptoms (e.g. vomiting, 
Jordan, Sippel, & Schmoll, 2007), most medical approaches fail to successfully alleviate nausea 
(for a review, see Sanger & Andrews, 2006). The mechanisms underlying such failure in reduc-
ing symptoms are not fully understood, but may involve the missed attempt to explicitly trigger 
the psychosocial components of nausea, for example, to take away high initial expectation of 
nausea (Colagiuri & Zachariae, 2010).   
Indeed, research has increasingly suggested that expectation plays a crucial role in the 
treatment of nausea, as it is a robust predictor of the actual experience of nausea. For example, 
in patients receiving chemotherapy, expectation of nausea measured prior to the beginning of 




& Morrow, 2001), more so than other personal variables, like age, gender or experience with 
nausea in the past (Montgomery & Bovbjerg, 2001). When making precise distinctions of ex-
pected nausea, Colagiuri and colleagues (2008) found that patients classified as highly ex-
pectant experienced more nausea than all other classifications (i.e. somewhat, slightly, no ex-
pectation). The authors concluded that patients with high initial expectations of nausea appear 
to be at particular risk of developing chemotherapy induced nausea and that it is important to 
find treatments which alleviate fearful expectations in these patients (Colagiuri & Zachariae, 
2010). This was also shown to be true in cancer patients treated with radiotherapy: nausea could 
effectively be reduced following sham acupuncture but only in those subjects who really be-
lieved that the treatment would effectively prevent nausea (Enblom et al., 2012).  
In general, expectation plays a crucial role in placebo interventions, and underlying PFC 
activity has been suggested to modulate expectation-specific mechanisms. For example in Alz-
heimer patients, a local anesthetic was less effective when the expectation component was ab-
sent (Benedetti et al., 2006). The expectation component could be studied in isolation in an 
open-hidden design, by administering the drug covertly (hidden condition) versus overtly (open 
condition). The analgesic placebo response in Alzheimer patients that also showed abnormal 
PFC activity was almost completely absent. 
Overall, the investigation of cortical top-down mechanisms of the placebo effect in nau-
sea, particularly expectation, plays a crucial role in understanding the underlying mechanisms 
of the placebo effect in nausea and thus may explain why nausea is relatively sensitive to pla-
cebo interventions. 
1.5 This Study and Its Hypothesis 
The present study was designed to investigate whether individuals who receive a placebo- 
intervention (i.e. a sham acupuncture combined with a positive verbal suggestion) would show 
decreased nausea ratings compared to a group who received no treatment and if so, whether this 
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difference could be evidenced by changes in EEG outcomes, in terms of stress and expectancy. 
Based on previous literature, the following main hypothesis were formulated:  
Placebo intervention would directly reduce the initial level of expected nausea, indexed 
by decreased NRSs and changes in the PFC and ACC during the anticipation phase in the pla-
cebo group compared to the control group (Amanzio, Benedetti, Porro, Palermo, & Cauda, 
2013, Benedetti et al., 2006). The anticipation phase in the present study is the period following 
verbal placebo instruction - or the instruction that they would not receive any treatment in the 
control group - before the nausea induction has been commenced. 
Placebo intervention would alleviate perceived nausea (i.e. placebo effect on nausea, 
Müller et al., 2016), indexed by decreased NRSs and changes in nausea related brain activities 
in the placebo group compared to the control group (e.g. decreased delta power, Hu et al., 1999; 
or changes in frontal or anterior cingulate activity, Farmer et al., 2015). 
Placebo intervention would attenuate perceived stress during acute nausea in the placebo 
group compared to the control group, which would be indexed by decreased cortisol and amyl-
ase levels. Interestingly, changes in PFC activity have been linked to nausea related ANS 
changes (Toschi et al., 2017). Therefore, the placebo-induced stress reduction was also assumed 
to be accompanied by altered PFC activity in the placebo group compared to the control group.  
Besides expectation and stress, also, reward-specific mechanism have been proposed to 
play a crucial role in the modulation of placebo responses (de la Fuente-Fernández, 2001, 2004), 
therefore self-reported positive aspects of motivation (Carver & White, 1994) were hypothe-
sized to enhance nausea-related placebo responses. In contrast, negative aspects of motivation 





The present study focuses on data collected at the Institute of Medical Psychology, Lud-
wig-Maximilians-University Munich, as part of a “Deutsche Forschungsgemeinschaft” (DFG) 
grant (ME3675/1-1) on “Effects of emotional context and tactile stimulation on the placebo 
response in a nausea model” in healthy individuals. 
2.1 Participants  
In total, 90 (45 females, 45 males) healthy participants were recruited for the study, be-
tween March, 2014 and April, 2015. They were recruited via flyers, advertisements on our in-
stitute homepage, an LMU email distribution list, and screening phone calls (to check for eligi-
bility). The recruitment was addressed to people who tend to suffer from motion sickness.  
To reduce potential confounding sources, participants were identified based on the fol-
lowing preliminary inclusion criteria: age between 18 and 50, right-handed (Chapman & Chap-
man, 1987), normal or corrected-to-normal vision and hearing, body mass index between 18 
and 25. Exclusion criteria included: ongoing pregnancy, current drug use, alcohol or drug abuse, 
implant devices or metal implants, regular medication use (except hormonal contraceptives, 
thyroid medications, allergy medications), history of diseases of the inner ear, skin diseases, 
diabetes, cardiovascular disease, epilepsy, cancer, history of blood-clotting disorders or ten-
dency for thromboembolic diseases, ongoing acute disease, surgery during the past 4 weeks, 
and any prior participation in a placebo or nocebo experiment.  
After fulfilling preliminary inclusion criteria, participants were asked to complete the mo-
tion sickness susceptibility questionnaire (MSSQ). This questionnaire ascertains how vulnera-
ble one feels to motion sickness and which kinds of motion are critical. Only subjects who rated 
significant susceptibility (≥ 80 on a 200 point scale) were asked to go through a pre-test session. 
The pre-test session aimed to test their sensibility to a nauseating stimulus. Participants were 
only included in the main experiment (control – and testing day) if moderate nausea was 
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reached. All participants provided written consent to a protocol approved by the LMU ethical 
review committee. Participants were compensated with 100 euros after completion of study.  
2.2 Vection Drum 
Nausea was induced in the context of motion sickness, which was simulated by means of 
a vection drum. The drum consisted of a curved shaped blank screen which was placed 30 cm 
distal to the participant’s head. Black and white stripes were presented on the screen on a rotat-
ing basis from left to right at 60 degrees per second. The left-to-right horizontal translation 
induces a circular vection sensation wherein participants experience a false sensation of trans-
lating to the left (Napadow et al., 2013). This in turn produces illusory self-motion, which 
causes moderate nausea in subjects who are predisposed to motion sickness (Müller et al., 
2016). The present method is similar to a ‘rotating’ optokinetic drum successfully applied in 
previous studies (Gianaros et al., 2001; Levine et al., 2006), but here the drum did not rotate, 
only the stripes were in regular motion. This allowed participants to sit still, which was im-
portant for EEG quality. 
2.3 Placebo Device  
Figure 1 illustrates the location of the sham- and the real acupuncture point. A placebo, 
‘sham acupuncture point stimulation’ was used, which was applied with a transcutaneous elec-
trical nerve stimulation (TENS) device (Digital EMS/TENS unit SEM 42, Sanitas, Uttenweiler, 
Germany). In contrast to real acupuncture needles, the TENS device works through electrical 
nerve stimulation acting via two electrodes that can be placed on the skin. It also includes a 
nonspecific massage program (somatosensory stimulation). Both types of stimulation cause a 
tingling sensation about the electrodes site, making the two difficult to distinguish.  
In the TENS group, the two electrodes were placed at the ‘P6’ acupuncture point, which 
is located at the antebrachial region of the forearm, 2 cun (ca. 6,67 cm) distal to the anterior 




(hertz), with a current between 7 and 13 mA (milliampere; Pfab et al., 2011). 
In the placebo condition, the two TENS electrodes were placed around a dummy point at 
the left and right forearm. The dummy point was evidenced to have no specific acupuncture 
effects (Witt et al., 2012). Its exact location is at the ulnar side of the forearm, a six centimeter 
distance to the elbow. The level of the tingling can be regulated and was adjusted based on 
participant’s feedback to a low intensity level but clearly noticeable. During placebo instruc-
tion, participants were informed to either receive placebo or real intervention, though the ex-
perimenter always pretended to place the electrodes at real acupuncture points and to switch on 
nerve stimulation.  
Figure 1. Diagram depicting the real acupuncture point (PC6, black dot) and the sham acupunc-
ture point (grew dot) at the right forearm, on which the TENS (transcutaneous electrical nerve 
stimulation) electrodes were attached according to the assigned condition (real treatment: TENS 
at PC6, simple placebo: attaching TENS electrodes to the sham acupuncture point with the 
TENS device turned off, enhanced placebo: attaching TENS electrodes to the sham acupuncture 
point and turning on a massage program which induced somatosensory stimulation). 
2.4 Verbal Instruction  
After the baseline measures, the randomization envelope was opened by the experimenter. 
Subjects assigned to TENS as well as sham acupuncture point stimulation were instructed that 
they would receive a therapy for nausea and that the therapy could either be a placebo or a real 
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TENS treatment. Next, the experimenter articulated that nausea was found to be associated with 
gastric abnormalities and that the TENS therapy was shown to positively influence stomach 
activity (Pfab et al., 2011), thus prevent motion sickness induced nausea (Streitberger et al., 
2006).  
Additionally, subjects were advised that the treatment will start ten minutes prior to the 
nausea induction because then positive treatment outcome was shown to be most effective 
(Ezzo et al., 2006). In contrast, participants assigned to the no-treatment group were instructed 
not to receive any treatment in order to measure spontaneous responses to the nauseating stim-
ulus. In order to avoid frustration in the no-treatment group, the importance of control groups 
in medical studies was also explained. The very same placebo instruction has been shown to 
powerfully induce placebo effects in females, in nausea related behavioral as well as bodily 
correlates (Müller et al., 2016). 
2.5 Group Assignment 
Table 1 presents an overview of the four study groups and their conditions on day 1 and 
day 2. The group assignment was randomized single-blind. To guarantee comparable baseline 
data across all subjects, the randomization envelopments were opened right after completion of 
the baseline measurement (t=-10). The participants were informed that they would either re-
ceive intervention, placebo, or no treatment. No information was given about the probability of 
the actual group assignment. Only 10% received real treatment, 45% placebo, and 45% no in-
tervention, respectively. The data conducted in the real treatment group was not of interest to 
the present study. The reason for implementing the TENS group was to provide a meaningful 
and ‘relatively’ truthful expectancy manipulation, which also fulfilled the ethical standards not 





Table 1. Design of the present study showing conditions for each group across the exper-
iment 
Note. Nausea was induced at both days across all groups. Only placebo group received intervention at day 2: 
Enhanced placebo group received sham acupuncture with somatosensory stimulation: TENS massage program at 
fake acupuncture point. Simple placebo group received sham acupuncture without somatosensory stimulation: 
TENS device stayed off but electrodes were placed at fake acupuncture point. Real acupuncture group received 
electrical nerve stimulation at real acupuncture point (PC6). TENS: transcutaneous electrical nerve stimulation. 
2.6 Self-Report Measures  
2.6.1 Expectation, Nausea and Stress  
Ratings on numeric rating scales (NRS) for expected nausea (on a ‘10’-point NRS, with 
‘0’ indicating no nausea and ‘10’ maximal tolerable nausea), perceived nausea (moderate nau-
sea corresponds to ≥‘5’ on a ‘10’-point NRS, with ‘0’ indicating no nausea and ‘10’ maximal 
tolerable nausea), and perceived stress (‘10’-point NRS, with ‘0’ indicating no stress and ‘10’ 
maximal stress) were obtained. 
2.6.2 Hospital Anxiety and Depression Scale 
Placebo interventions have been shown to activate emotional components (Petrovic et al., 
2005), therefore the contribution of mood disorders related to anxiety and depression was as-
sessed using the Hospital Anxiety and Depression scale (HADS-A, HADS-D, Zigmond & 
Snaith, 1983). In total, the HADS consists of 14 items, seven of them are related to anxiety (i.e. 
I feel tense) and seven to depression (i.e. I feel as if I am slowed down). Each question is rated 
on a ‘0’ to ‘3’-point scale, which leads to a maximum score of ‘21’ for each scale. A sum score 
of greater than ‘7’, which also was the cut-off score of including participants in the present 
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study, was suggested to indicate mood disorders (Snaith, 2003). 
2.6.3 State and Trait Anxiety  
To control for emotional variations between groups and testing days, trait and state anxi-
ety was ascertained using the State-Trait Anxiety Inventory (i.e. STAI-State and STAI-Trait; 
Spielberger, 2010). STAI-Trait was rated on the control day. STAI-State was conducted twice, 
at the control- and placebo day. Participants were requested to report on a ‘4’-point scale how 
much 20 statements apply to them ‘at this moment’ (i.e. state) and in general (i.e. trait). Items 
described both the absence of anxiety (e.g. ‘I am calm’) and the presence of anxiety (i.e. ‘I am 
worried.’), with higher scores indicating greater levels of anxiety. The questionnaire was ad-
ministered by paper-and-pencil. 
2.6.4 Motivation 
Motivational aspects have been shown to modify placebo responses (de la Fuente-Fer-
nández et al., 2001). It is possible that the level of motivation also modulates the placebo effect 
in nausea. Therefore, aspects of motivation underlying behavior were obtained at baseline dur-
ing day 1 using the behavioral inhibition - and behavioral approach system scale (BIS/BAS; 
Carver and White, 1994). Participants were required to state the extent to which the 24 state-
ments applied to them. Items described both negative (BIS, e.g. ‘Criticism or scolding hurts me 
quite a bit.’) and positive (BAS drive, e.g. ‘I go out of my way to get things I want’) aspects of 
motivation. The questionnaire was administered by paper-and-pencil. 
2.7 Cortisol and Amylase 
To measure the humoral response of the hypothalamic-pituitary-adrenal (HPA)-axis and 
the sympathetic nervous system, respectively, saliva samples of cortisol and alpha-amylase 
were collected before and after baseline and at acute nausea (see Figure 3) by a cotton swab, on 




each session, saliva concentrations were centrifuged at 2000 rpm at 4°C and 2x 300μl per sam-
ple stored at -20°C.  
2.8 Electroencephalography Recordings  
Figure 2 illustrates the exact positions coordinates of the 32-electrodes used in the present 
study. EEG was recorded using the ActiveTwo system (BioSemi) with thirty two-channels ar-
rayed in a regular distribution based on a standard 10-20 system. Additionally, two external 
mastoid channels as well as horizontal and vertical electrooculography (EOG) were recorded. 
After placing the electrodes, the offset signal was controlled individually for each channel and 
kept below 20 mV. Sampling rate was 2,048 (2 KHz). Data was offline down sampled to 265 
Hz and re-referenced to the mastoids after a 50-Hz high cut-off filter was applied.   
 
Figure 2. Position coordinates of the 32-electrodes for the BioSemi headcaps, which were used 
in the present study. 
  




The sessions included verbal ratings, electroencephalography (EEG), electrocardio-
graphy (ECK), electrogastrogram (EGG), saliva and blood collection, and several question-
naires. From this large dataset, this study focuses on: (1) the following questionnaires: motion 
sickness susceptibility questionnaire (MSSQ, Golding, 2006), German version of hospital de-
pression scale (HADS-A and HADS-D, Zigmond & Snaith, 1983), and behavioral inhibition - 
and behavioral approach system scale (BIS/BAS, Carver & White, 1994), (2) verbal ratings on 
a numeric scale of expected nausea, perceived nausea, and perceived stress (Müller et al., 2016), 
(3) saliva samples of cortisol and amylase, and (4) 32- channel EEG recordings.  
The study included two experimental sessions, referred to as day 1 (control condition) 
and day 2 (test condition). At each session and across all subjects, nausea was induced by means 
of the vection drum, however randomization to either placebo intervention or control was ap-
plied only at day 2.  
Day 1 and day 2 were conducted on two consecutive days, at least 48 hours apart, con-
stantly between 14:00 and 19:00 o’clock. This was important to avoid circadian influences, 
which were shown to affect the hormone level (Ca & Eb, 1999; Czeisler & Klerman, 1999). 
Participants were instructed not to eat or drink liquids other than water three hours prior to the 
experiment. After that, the EEG net was applied. Saliva probes were collected before baseline 
measurement (amylase and cortisol), after the nauseating stimulus was stopped (peak of in-
duced nausea, amylase), and at the end of each session (cortisol). Furthermore, at baseline and 
during nausea exposure ratings on the NRS for nausea (moderate nausea corresponds to ≥‘5’ 
on a ‘10’-point NRS, with ‘0’ indicating no nausea and ‘10’ maximal tolerable nausea) and 
stress levels (on a ‘10’-point NRS) were obtained. Furthermore, before baseline and directly 
following the expectancy manipulation, participants rated the maximal level of expected nausea 




3.1 Nausea Exposure  
Study day 1 involved three saliva probes, nausea induction, NRS of expected and per-
ceived nausea, perceived stress, and perceived motion sickness as well as EEG recordings. It 
included a ten minute baseline followed by a ten minute rest measurement during which partic-
ipants sat in front of a blank screen and were instructed to look straight ahead and keep still. 
Next, the nauseating stimulus was turned on for 20 minutes. The session was completed with a 
resting period of 15 minutes during which participants again sat in front of the blank screen, 
while looking straight ahead and keeping still. 
3.2 Placebo Intervention  
Figure 3 presents an overview of the study protocol on day 2. This session comprised 
three saliva probes, nausea induction, NRS of expected and perceived nausea, perceived stress, 
and perceived motion sickness as well as EEG recordings and sham acupuncture point stimu-
lation for the placebo group. After the ten minutes baseline measurement, participants were 
randomized to receive either no treatment (control group) or sham acupuncture point stimula-
tion (placebo group). Immediately following randomization, participants in the placebo group 
received a standardized instruction of positive verbal suggestion of nausea improvement (see 
above, Placebo Instruction) and the device for the sham acupuncture point stimulation was ap-
plied and switched on for twenty minutes. After ten minutes of intervention or rest, the nause-
ating stimulus was presented to the participants for twenty minutes. After the first ten minutes 
of nausea exposure the placebo intervention was stopped (device was turned off), so that the 
last ten minutes of nausea exposure were free of any uncontrolled actions through the device or 
the electrodes.  
In contrast, participants in the control group were informed that they would not receive 
any treatment. Consistent with day 1, the experiment was completed with a 15 minute resting 
period during which participants were asked to look at the blank screen. 




Figure 3. Overview of the study protocol on day 2. Expectancy manipulation and sham acu-
puncture was only applied in the placebo group. The control group received no intervention. 
Abbreviations: EEG: Electroencephalography. aNumeric rating scale (0-10). 
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4. Data Analysis 
4.1 Behavioral 
In total, the behavioral measures consisted of the following NRS: (1) expected nausea, 
(2) perceived nausea, and (3) perceived stress. At day 1 and day 2, the primary analyses focused 
on measures during baseline and nausea exposure. Expected nausea was directly rated after 
expectancy manipulation. Thus, the following means of ratings during these time points (note: 
time points referred to as t) were computed: 
(1) Expected nausea at day1 and day 2, computed as mean NRS scores after baseline (t=-10, which 
was shortly after the expectancy manipulation at day 2) minus expected nausea rated at the 
beginning of the session (t=-20), with lower scores reflecting decreased levels of expected nau-
sea. 
(2) Perceived nausea (at day 1 and day 2: rated every minute during baseline from t=-20 to t=-10, 
and acute nausea from t=+10 to t=+20), operationalized as mean NRS scores during acute nau-
sea minus nausea rated during baseline, higher scores indicating increased magnitude of nausea 
induction. 
(3) Perceived stress at day 1 and day 2, computed as NRS scores rated at acute nausea (t=+10) 
minus at rest (t=-20), with higher scores reflecting increased stress levels. 
(4) Placebo effects (spontaneous changes from day 1 to day 2 in the control group, respectively) 
on expected nausea, perceived nausea, and stress were defined as baseline corrected mean NRS 
scores [mean NRS scores during nausea minus mean NRS scores during baseline] at day 1 
minus at day 2, whereby higher scores indicate greater placebo effects. 
4.2 Amylase and Cortisol 
Salivary amylase and cortisol levels were ascertained via ‘cortisol saliva assay’ and ‘al-
pha-amylase saliva assay’ kit from IBL International GMBH (catalogue number of cortisol kit: 
RE52611 and amylase: RE80111). All saliva samples were analyzed in duplicate and performed 
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following the manufacturer’s protocol. Finally, the values of amylase and cortisol levels at acute 
nausea were logarithmized to a natural factor and corrected for the levels measured at baseline 
by computing (for amylase: level at acute nausea minus level at baseline, for cortisol: level at 
the end of the session minus level at baseline). Final analyses were conducted in SPSS. 
4.3 Electroencephalography 
The EEG data was processed offline using Brain Vision Analyzer 2.0 (Brain Products 
GmbH, Gilching, Germany). First, ‘Sinc-Interpolation’  was used to down sample the EEG data 
to a rate of 256-Hz as well as a low cut-off of 0.5 Hz and a high cut-off of 50 Hz with a notch 
filter of  50-Hz which was applied. Further, gross artifacts were removed and EEG data was re-
referenced to the mastoids. Next, ocular ICA was run to remove blink artifacts. Bad individual 
channels were spatially weighted and linear interpolated. To exclude any remaining artifacts, a 
final semi-automatic artifact rejection was applied.  
Additionally, voltage levels at the 32 electrodes were replaced by valid head coordinates 
through the current source density (CSD; order of splines: 4, max. degree of Legendre polyno-
mials: 10). Then, each ten minute period was segmented into one second segments and fast 
Fourier transformed (FFT), transforming EEG data from the time into the frequency domain. 
Finally, mean values of the following frequency bands were exported and analyzed in SPSS: δ, 
0.5-4 Hz, θ, 4.1-8 Hz; α, 8.1-13 Hz; β I, 13.1-20 Hz; β II, 20.1-30 Hz; and total EEG (0.5-30 
Hz) for both the baseline period as well as during nausea exposure (frequency bands adapted 
by Hu, 1999).  
4.3.1 Delta Power  
Delta power has been shown to be associated with nausea as well as stress (Hu, 1999; 
Hall et al., 2007). Therefore, delta frequency band was extracted from electrodes C3 and C4. 
Specifically, the mean delta values of spectral power were extracted from EEG recordings dur-
4. Data Analysis 
29 
 
ing baseline and acute nausea on both day. Next, the delta percentage of total power was com-
puted by dividing delta spectral power by total spectral power (total EEG power, 0.5-30 Hz). 
Finally, to investigate the placebo effect on nausea related changes in Delta percentage of total 
power, an additional variable was computed indicating nausea related increase in Delta percent-
age of total power (computed as: Delta percentage of total power during nausea minus Delta 
percentage of total power during baseline).  
4.3.2 Exact Low Resolution Electromagnetic Tomography  
To localize nausea and placebo related brain activation, exact low resolution brain elec-
tromagnetic tomography algorithm (eLORETA), invented by Pascual-Marqui (Pascual-Marqui, 
2002; Pascual-Marqui, 2007) and freely available at the LORETA webpage 
(http://www.uzh.ch/keyinst/loreta.htm), was applied. Out of many, it is one of the most com-
monly used algorithms to estimate the location of EEG sources (Grech et al., 2008). By now, 
eLORETA has been evidenced as an accurate solution to map the origin of EEG data recorded 
at the scalp, shown by studies comparing LORETA to other source localization methods, for 
example to fMRI (Mulert, 2004; Vitacco, 2002), positron emission tomography (PET; Piz-
zagalli, 2004) or implanted electrodes in epilepsy patients (Zumsteg, 2006).  
eLORETA estimates the exact current density of different frequencies at 6239 voxels at 
5mm spatial resolution in the grey matter based on the Montreal Neurological Institute (MNI)-
reference brain. eLORETA analyses were based on recordings of 32-channel EEG, measured 
during baseline, during anticipation period (in the placebo group, this is the period following 
verbal instruction before the nauseating stimulus was turned on; in the control group this is the 
period following instruction that they would receive no treatment), and during nausea exposure 
(each period consist of 10 minutes of EEG recording). The raw EEG data was preprocessed 
offline in BVA (see above), segmented into 1 minute sequences, and exported as .dat files. In 
LORETA the 1 minute sequences were merged into SLOR files on which the following analysis 
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was run separately for each participant: 
(1) To indicate regions presenting brain activity related to nausea, voxel-wise paired t-tests were 
performed by comparing participants at rest and during nausea exposure at day 1 (control con-
dition). 
(2) To identify regions showing placebo-induced changes in nausea-related activity, voxel-wise 
unpaired t-tests were performed, comparing the magnitude of nausea at day 1 to the magnitude 
of nausea at day 2, separately for the control and the placebo group.  
(3) To reveal regions reflecting changes in activity due to the expectation manipulation, voxel-wise 
paired t-tests were conducted, comparing the EEG recordings on day 2 during baseline to the 
recordings during anticipation period, separately for the control and the placebo group. 
Study groups were stratified by gender. Significant nausea or placebo related changes in 
the different frequency oscillations (δ, 0.5-4 Hz, θ, 4.1-8 Hz; α, 8.1-13 Hz; β I, 13.1-20 Hz; β 
II, 20.1-30 Hz) were defined at p ≤ 0.05.   
4.4 Statistical Analysis  
To examine the magnitude of nausea induction and the placebo effect on nausea, which 
was defined as the decrease in the magnitude of nausea sensation from day 1 to day 2 in the 
placebo group compared to the control group (for the behavioral as well as for the EEG data) 
‘mixed’ 2x2x2 analyses of variance (ANOVAs) was conducted. The between subject factors 
were defined as group (no treatment vs sham acupuncture point stimulation) and sex (male vs 
female), and the within subject factor as day (control condition versus placebo condition). Pre-
sent ANOVA results were Greenhouse-Geisser corrected. Post hoc t-tests and univariate ANO-
VAs were conducted following significant ANOVA findings (p ≤ 0.05). To evaluate the effects 
of expectation and stress on nausea and delta power as well as potential relationships between 
those variables, the degrees of Spearman´s rho correlations between baseline corrected mean 
NRS scores of perceived stress, perceived nausea, and the percentage of delta power in C3 and 
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C4 were assessed. To evaluate potential mechanism of the placebo effect, the degrees of Spear-
man´s rho correlations between the placebo effect on expected and perceived nausea, perceived 
stress, and delta power in C3 and C4 were conducted.  
Significant nausea or placebo related changes were defined at p ≤ 0.05. Finally, due to 
frequently occurring sex differences in placebo studies (Meissner et al., 2016), the study groups 
were stratified by gender. 
 
  




5.1 Demographics and Self-Reported Data 
Out of 494 individuals who responded to initial recruitment, 384 (203 females and 181 
males) scored at least 80 in the MSSQ and were invited to participate in the pre-test session. In 
total, 245 individuals completed the pre-test session among which 121 (63 females and 58 
males) tested positive (in the nausea rating) and were invited to the experimental days. After 
day 1, eleven females and eight males dropped out because they either were no longer interested 
in completing the study, had trouble with taking blood samples (fear, circulation problems, or 
hidden veins), or the level of nausea was less than moderate.  
In total, 100 subjects completed the study. To fulfill ethical standards, ten participants 
received real treatment, though this experimental condition was of no interest to the present 
study.  Thus, the present data focuses on data of 90 participants, split into two groups (30 control 
and 60 placebo participants). The mismatched group numbers (30 relative to 60) were a conse-
quence of the initial hypothesis that a sham acupuncture condition with somatosensory stimu-
lation (‘enhanced placebo group’, including 30 subjects) would induce more powerful placebo 
effects on nausea compared to a sham acupuncture condition without stimulation (‘simple pla-
cebo group’, including 30 subjects). However, this did not turn out to be the case. Instead, both 
placebo groups displayed similar levels of decreased nausea (these results will be reported in 
detail in a separate dissertation). Preliminary analyses of the psychophysiological outcomes 
also did not show any difference between the two placebo groups. Consequently, the two groups 
were pooled for the present analysis to increase power. Sex was equally distributed across the 
two groups. Table 2 summarizes the demographic data and questionnaires at baseline and illus-
trates that no significant differences existed in baseline characteristics between the control and 





Table 2. Demographic sample description separately for control and placebo group at 












Note. Entries show mean and standard deviation (SD), p-values (One-Way ANOVA´s), motion sickness suscepti-
bility questionnaire (MSSQ), hospital depression scale (HADS-D), hospital anxiety scale (HADS-A), body mass 
index (BMI), education (sum of total number of years of school and university), behavioral inhibition and approach 
system scale (BIS/ BAS), state-trait anxiety inventory (STAI). 
5.2 Behavioral Data 
Table 3 summarizes the behavioral and humoral data as well as delta percentage of total 
power conducted at day 1, and shows that no significant differences existed between the control 
and the placebo group at the control condition (i.e. expected and perceived nausea, perceived 
stress, perceived motion sickness, cortisol, amylase, delta power, all p > 0.05). In contrast and 
in line with our main hypothesis, one-way ANOVA´s displayed significant group differences in 
expected- and perceive nausea as well as perceived stress at day 2 (all p ≤ 0.01, see Table 4).  
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Table 3. Behavioral, EEG, and humoral sample description separately for placebo and 
control group at times of acute nausea (average over t=+10 to +20) at day 1 
 
Note. Entries show mean, standard deviation (SD), and p-values (One-Way ANOVA´s, * indicates p ≤ .05). Day 
1 (control condition, ctrl), numeric rating scale (NRS), logarithmized (ln), all values were baseline corrected (mi-
nus baseline recordings, bc), average (avg). 
Table 4. Behavioral, EEG, and humoral sample description separately for placebo and 
control group at times of acute nausea (average over t=+10 to +20) at day 2 
 
Note. Entries show mean, standard deviation (SD), and p-values (One-Way ANOVA´s, * indicates p ≤ .05). Day 
2 (placebo condition versus no treatment condition, test), numeric rating scale (NRS), logarithmized (ln), all values 




5.2.1 Expected Nausea 
A main effect of day (control versus intervention day) emerged for expected nausea (F(1, 
80) = 6.13, p = 0.02) as well as a two-way interaction between day x group (F(1, 80)=5.87, 
p=.02). As hypothesized, the interaction was driven by lower levels of expected nausea (M = 
4.16, SD = 0.29) in the placebo group compared to the control group (M = 5.60, SD = 0.29) at 
day 2 (t(56) = 4.19, p = 0.00; Figure 4). This indicates that our expectancy manipulation elicited 
the intended effect on a behavioral level, i.e. positive believe led to lower perceived nausea 
through the intervention. Neither a two-way interaction of day x sex nor a three-way interaction 












Figure 4. Baseline corrected (bc) means of expected nausea for the control (n=30) and the pla-
cebo group (n=60), rated at t = -10, separately for day 1 and day 2. NRS: ‘10’-point Numeric 
rating scale, with ‘0’ indicating no expected nausea and ‘10’ maximal level of expected nausea. 
**indicates p ≤ 0.001. Error bars indicate standard error. 
5.2.2 Perceived Nausea 
A main effect of day (F(1, 86) = 128.08, p = 0.00) as well as an interaction between day 
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x group (F(1, 86) = 47.66, p = 0.00) were observed. Post-hoc tests showed that this effect re-
sulted from a significant decrease in perceived nausea in the placebo group compared to the 
control group at day 2 (F(1, 79) = 7.86, p = 0.01; day 2: control group: M = 4.82, SD = 0.32, 
placebo group: M = 2.37, SD = 0.27). By contrast, at day 1 both groups perceived similar levels 
of nausea (p ≥ 0.05; day 1: control group: M = 5.60, SD = 0.27, placebo group: M = 5.59, SD = 
0.24; Figure 5). These findings indicate that the placebo intervention successfully induced a 












Figure 5. Baseline corrected (bc) mean NRS scores of perceived nausea for the control (n=30) 
and the placebo group (n=60), average over t = +10 to +20, separately for day 1 and day 2. 
NRS: Numeric rating scale. * indicates p ≤ 0.01. Error bars indicate standard error. 
5.2.3 Perceived Stress 
The ANOVA based on stress ratings conducted at time point +20 minutes at each session 
indicated no placebo effect on stress, only a main effect of dayt emerged. This was due to a 
reduction in stress from day 1 to day 2 (t(77) = 6.52, p = 0.00; day 1: M = 3.76, SD = 2.34; day 
2: M = 1.96, SD = 2.40).  




2 revealed a main effect of day (F (1, 74) = 30.71, p = 0.00), an interaction between day x group 
(F (1, 74) = 4.88, p = 0.03), and a three-way interaction between day x group x sex (F(1, 74) = 
6.10, p = 0.02). This was due to blunted stress levels in the females’ placebo group compared 
to the control group at day 2 (F(1, 44) = 9.80, p = 0.00; females: day 1: control group: M = 2.83, 
SD = 0.55, placebo group: M = 2.97, SD = 0.33; day 2: control group: M = 2.9, SD = 0.46, 
placebo group: M = 0.95, SD = 0.38; Figure 6: A), which was not true in females at day 1. 
Neither was there a significant group difference in males at day 1 or day 2 (p ≥ 0.05; day 1: 
control group = 2.9±0.38, placebo group=2.65±0.37; day 2: control group = 2.65±0.37, placebo 
group = 1.22±0.37). In contrast, the males showed a stress reduction above both groups from 
day 1 to day 2 (t(32) = 4.60, p = 0.00; Figure 6: B).  
 
Figure 6. Baseline corrected (bc) NRS scores of perceived stress rated at t = +10 for the control 
(n=30) and the placebo group (n=60) at day 1 and day 2 for (A) females and (B) males. NRS: 
Numeric rating scale. ** indicates p ≤ 0.001. Error bars indicate standard error. 
5.3 Humoral Stress Parameter 
5.3.1 Cortisol  
For cortisol, the ANOVA resulted in a main effect of day (F(1, 85) = 6.13, p = 0.02) and 
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a trend towards an interaction between day and sex (F(1, 85)=3.79, p=0.06). This was driven 
by reduced stress levels in females at day 2 compared to day 1 (t(44) = 3.17, p = 0.00; female 
cortisol level day 1: M = 0.33, SD = 0.79, female cortisol level day 2: M = -0.06, SD = 0.67, 
Figure 7), which was not the case in males (p ≥ 0.05; male cortisol level day 1: M = -0.03, SD 
= 0.68, male cortisol level day 2: M = -0.03, SD = 0.78; Figure 7). No main or interaction effects 









Figure 7. Mean levels of cortisol, logarithmized (ln) and baseline corrected (bc), separately for 
females and males at day 1 and day 2. Error bars indicate standard error. 
5.3.2 Amylase 
There were no main effects on amylase neither for day nor for group or sex, or interac-
tional effects (all p´s ≥ 0.05; amylase level in the control group at day 1: M = 4.75, SD = 0.58, 
and day 2: M = 4.65, SD = 0.59; amylase level in the placebo group at day 1: M = 4.67, SD = 












Figure 8. Mean levels of amylase conducted at t = +20, logarithmized (ln) and baseline cor-
rected (bc), separately for the placebo and the control group at day 1 and day 2. Error bars 
indicate standard error. 
5.4 Electroencephalography: Fast Fourier Transformation 
5.4.1 Percentage of Delta Power in C4 
A repeated measures ANOVA comparing day, groups and sex in percentage of delta power 
(0.5 – 4 Hz) in the C4 electrode revealed no significant effect of day or dayby group (p ≥ 0.05), 
though there was a significant three-way interaction between day, group, and sex (F(1, 76) = 
4.67, p = 0.03). A univariate ANCOVA, separately conducted for sex, with group as the between 
subject factor and the increase of delta power on day 2 (difference between delta power at acute 
nausea minus at baseline) as the dependent variable, controlled for the increase of delta power 
at day 1 as a covariate revealed a significant group effect on the percentage of delta frequency 
during nausea at day 2 in females only (females: F(1, 38) = 4.02, p = 0.05; female control group 
increase delta power in C4 day 1: M = 0.05, SD = 0.07, day 2: M = 0.06, SD =0.14; female 
placebo group increase delta power in C4 day 1: M =0.04, SD =0.12, day 2: M = -0.01, SD 
=0.10; Figure 9: A; males: p ≥ 0.05; male control group increase delta power in C4 day 1: M = 
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0.05, SD =0.15, day 2: M = -0.02, SD =0.11; male placebo group increase delta power in C4 
day 1: M = 0.03, SD =0.13, day 2: M = 0.03, SD =0.11, Figure 9: B). This suggests a placebo 
effect on the percentage of delta power above central areas in females but not in males.  
Figure 9. Percentage of delta power of the total FFT (fast Fourier transformed) spectrum at 
acute nausea [averaged over t=+10 to +20] in (A) females and (B) males at day 1 and day 2, 
separately for the placebo (n = 30) and the control participants (n = 60), baseline corrected (bc). 
5.4.2 Percentage of Delta Power in C3 
There was a main effect of day (F(1, 76) = 3.97, p = .05), though post-hoc t-test across 
groups indicated no significant differences between the nausea related percentage of delta 
power on day 1 versus day 2 (p ≥ 0.05; increase delta power in C3 at day 1: M = 0.03, SD = 
0.11, day 2: M = 0.00, SD =0.10). No other significant main effects or interactions were found 





5.5 Gender and the Placebo Effect  
In order to understand the influence of gender, table 5 (day 1) and 6 (day 2) list stress 
related parameters (i.e. perceived behavioral stress at t = +10 and +20, increase in cortisol, 
amylase, and delta power) across control and placebo groups, separately for females and males 
(for more detail see section 5.6.3). A placebo effect was found only in the female group on delta 
power in C4 as well as on perceived stress at t=+10 minutes (for more detail see sections 5.2.3 
and 5.4.1).  
Table 5. Behavioral, EEG, and humoral parameters across control and placebo group, 
separately for females and males at times of acute nausea at day 1 
Note. Entries show mean, standard deviation (SD), and p-values (One-Way ANOVA´s, * indicates p ≤ .05, ** p ≤ 
.001), day 1 (control condition, ctrl), all values were baseline corrected (i.e. minus baseline recordings, bc) humoral 
parameters were logarithmized (ln).  
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Table 6. Behavioral, EEG, and humoral parameters across control and placebo group, 
separately for females and males at times of acute nausea at day 2 
Note. Entries show mean, standard deviation (SD), and p-values (One-Way ANOVA´s, * indicates p ≤ 0.05, ** p 
≤ 0.001), day 2 (condition including sham intervention in the placebo group versus no treatment in the control 
group, test), all values were baseline corrected (i.e. minus baseline recordings, bc) humoral parameters were log-
arithmized (ln). 
5.6 Correlations  
5.6.1 Acute Nausea, Stress and Delta Power  
Table 7 shows the results of the correlation analysis (Spearman´s rho) across all subjects 
for expected and perceived nausea, perceived stress, cortisol and amylase as well as percentage 
of delta power in C3 and C4 at day 1. Perceived nausea was positively associated with expected 
nausea (rs (78) = 0.23, p = 0.04,), indicating that expected nausea may be a predictor of actual 
experience levels of nausea. Additionally, perceived nausea positively correlated with perceived 
stress (rs (78) = 0.60, p = 0.00, Figure 10: A), and an increase in cortisol (rs (89) =0.25, p = 
0.02; Figure 10: C). Furthermore, stress was associated with the rise in cortisol (rs (86) =0.26, 
p = 0.02; Figure 10: B) and there was a trend towards a positive relation between the increase 
of delta power in C3 and rise in cortisol (rs (85) =0.20, p = 0.07; Figure 10: D). This trend seems 
to be meaningful since the raw percentage of delta power in C3 was also significantly associated 
with the rise in cortisol (rs (86) =0.23, p = 0.03). Finally, in line with previous literature, there 
was no correlation between cortisol and amylase (p ≥ 0.05), despite the fact that they have both 




Table 7. Correlations including all reported variables across all subjects at day 1 
 
 
Note. A: expected nausea rated at t=+10, B: perceived nausea computed as the average of nausea rated at the NRS 
every minute from t=+10 to t=+20, C: perceived stress rated at t=+10, D: perceived stress rated at t=+20, E: loga-
rithmized cortisol levels assessed at t=+35, F: logarithmized amylase levels assessed at t=+20, G: percentage of 
delta power of the total FFT (fast Fourier transformed) spectral power in electrode C3, H: percentage of delta 
power of the total FFT spectral power in electrode C4. All values are corrected for baseline [mean values during 
nausea – mean values during baseline]. a indicates trend towards significant correlation p ≤ 0.08, * indicates p ≤ 
0.05, ** indicates p ≤ 0.001. 
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Figure 10. Scatterplots A-D. Positive correlations at day 1 between: (A) perceived stress (t = 
+20) and perceived nausea (average over t = +10 to +20); (B) perceived stress (t = +20) and 
logarithmized (ln) rise in cortisol (t = +35 minus t = -20); (C) perceived nausea (t = +10) and 
rise in cortisol; (D) percentage of delta power (average over t = +10 to +20) and ln rise in 
cortisol, all mean values are baseline corrected (bc) and presented across all subjects. a indicates 
trend towards significant correlation p ≤ 0.08, * indicates p ≤ 0.05, ** indicates p ≤ 0.001. 
5.6.2 Placebo Effect on Nausea, Stress and Delta Power 
Table 8 shows correlations across no-treatment subjects for the spontaneous changes in 
all reported variables. Table 9 shows correlations across placebo participants for the placebo 
effect on all reported variables. No significant correlations for any spontaneous changes from 




that the placebo effect on nausea would be regulated via expectation and stress modulation, no 
significant correlation between the placebo effect on nausea and stress, expectation, cortisol, or 
delta power emerged (all p > 0.05). However, there was a trend between the placebo effect on 
delta power in C3 and nausea (rs(51) = 0.26, p = 0.06). 
Table 8. Correlations across control group for spontaneous changes in all reported vari-
ables from day 1 to day 2 
Note. Spontaneous changes from day 1 to day 2 in A - H were defined as the baseline corrected mean values at 
day 1 minus the baseline corrected mean values at day 2. A: Expected nausea rated at t = +10, B: Perceived nausea 
computed as the average of nausea from t = +10 to +20, C: Perceived stress rated at t = +10, D: Perceived stress 
rated at t = +20, E: Logarithmized cortisol levels assessed at t = +35, F: Logarithmized amylase levels assessed at 
t=+20, G: Percentage of delta power of the total fast Fourier transformed (FFT) spectral power in electrode C3, H: 
Percentage of delta power of the total FFT spectral power in electrode C4. a indicates trend towards significant 
correlation p ≤ 0.08, * indicates p ≤ .05, ** indicates p ≤ 0.001. 
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Table 9. Correlations across placebo group for the placebo effect on all reported variables 
Note. Placebo effects on the variables A – H were defined as the baseline corrected mean values at day 1 minus 
the baseline corrected mean values at day 2. A: Expected nausea rated at t = +10, B: Perceived nausea computed 
as the average of nausea t = +10 to +20, C: Perceived stress rated at t = +10, D: Perceived stress rated at t = +20, 
E: Logarithmized cortisol levels assessed at t = +35, F: Logarithmized amylase levels assessed at t = +20, G: 
percentage of delta power of the total fast Fourier transformed (FFT) spectral power in electrode C3, H: Percentage 
of delta power of the total FFT spectral power in electrode C4. a indicates trend towards significant correlation p 
≤ 0.08, * indicates p ≤ .05, ** indicates p ≤ 0.001. 
5.6.3 Gender and the Placebo Effect in Nausea, Stress and Delta Power 
Since a placebo effect on delta power in C4 and stress at t = +10 was observed only in 
females, a correlation analysis stratified by gender which included placebo effects (spontaneous 
changes in the placebo group) was run on expected and perceived nausea and all stress relevant 
parameters. Due to the fact that some of the stress related parameters showed no reduction from 
day 1 to day 2, mean amylase and cortisol levels measured at day 2 (i.e. not subtracted by the 
data conducted at day 1) were also included in the correlation analysis. Table 10 – 13 shows 





Table 10. Correlations including spontaneous changes in nausea, delta power in C4 and 
stress, and stress-relevant parameters at day 2 for the female control group 
 
Note. Spontaneous changes from day 1 to day 2 in A - C were defined as the baseline corrected mean values at 
day 1 minus the baseline corrected mean values at day 2. A: Perceived nausea computed as the average of nausea 
from t = +10 to +20, B: Percentage of delta power of the total FFT spectral power in electrode C4, C: Perceived 
stress rated at t = +10. Variables D – G represent baseline corrected parameters conducted at day 2 (test). D: 
Perceived stress rated at t = +10, E: Perceived stress rated at t = + 20, F: Logarithmized amylase levels assessed at 
t=+20, G: Logarithmized cortisol levels assessed at t = +35. a indicates trend towards significant correlation p ≤ 
0.08, * indicates p ≤ 0.05, ** indicates p ≤ 0.001. 
Table 11. Correlations including spontaneous changes in nausea, delta power in C4 and 
stress, and stress-relevant parameters at day 2 for the male control group 
Note. Spontaneous changes from day 1 to day 2 in A - C were defined as the baseline corrected mean values at 
day 1 minus the baseline corrected mean values at day 2. A: Perceived nausea computed as the average of nausea 
from t = +10 to +20, B: Percentage of delta power of the total FFT spectral power in electrode C4, C: Perceived 
stress rated at t = +10. Variables D – G represent baseline corrected parameters conducted at day 2 (test). D: 
Perceived stress rated at t = +10, E: Perceived stress rated at t = + 20, F: Logarithmized amylase levels assessed at 
t = +20, G: Logarithmized cortisol levels assessed at t = +35. a indicates trend towards significant correlation p ≤ 
0.08, * indicates p ≤ 0.05, ** indicates p ≤ 0 .001. 
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Table 12. Correlations including placebo effect on nausea, delta power in C4, and stress, 
and stress-related parameters at day 2 for the female placebo group 
 
Note. Placebo effects in A - C were defined as the baseline corrected mean values at day 1 minus the baseline 
corrected mean values at day 2. A: Perceived nausea computed as the average of nausea from t = +10 to +20, B: 
Percentage of delta power of the total FFT spectral power in electrode C4, C: Perceived stress rated at t = +10. 
Variables D – G represent baseline corrected parameters conducted at day 2 (test). D: Perceived stress rated at t = 
+10, E: Perceived stress rated at t = + 20, F: Logarithmized amylase levels assessed at t = +20, G: Logarithmized 
cortisol levels assessed at t = +35. a indicates trend towards significant correlation p ≤ 0.08, * indicates p ≤0 .05, 
** indicates p ≤ 0.001. 
Table 13. Correlations including placebo effect on nausea, delta power in C4 and stress, 
and stress-relevant parameters at day 2 for the male placebo group 
Note. Placebo effects in A - C were defined as the baseline corrected mean values at day 1 minus the baseline 
corrected mean values at day 2. A: Perceived nausea computed as the average of nausea from t = +10 to +20, B: 
Percentage of delta power of the total FFT spectral power in electrode C4, C: Perceived stress rated at t = +10. 
Variables D – G represent baseline corrected parameters conducted at day 2 (test). D: Perceived stress rated at t = 
+10, E: Perceived stress rated at t = + 20, F: Logarithmized amylase levels assessed at t = +20, G: Logarithmized 
cortisol levels assessed at t = +35. a indicates trend towards significant correlation p ≤ 0.08, * indicates p ≤ 0.05, 





Among females only, the placebo effect on nausea was negatively associated with the 
amylase level at acute nausea at t = +35 at day 2 (rs(30) = -0.46, p ≤ 0.02; Figure 11: E). Addi-
tionally, the placebo effect on delta power in C4 negatively correlated with baseline corrected 
stress levels at t = +10 at day 2 (rs(30) = -0.41, p ≤ 0.05; Figure 11: F) and amylase level at day 
2 (trend, rs(23) = -0.40, p=0.06; Figure 11: G). No correlations were found for other stress 
related parameters, neither in females nor in males (p > 0.05). 
Figure 11. Scatterplots E - G. Negative correlations across female placebo subjects between (E) 
the placebo effect on delta power in C4 and baseline corrected mean scores of perceived stress 
(t=+10) at day 2; and (F) the placebo effect on nausea and baseline corrected amylase level 
(t=+20) at day 2; and (G) the placebo effect on delta power in C4 and baseline corrected amylase 
level (t=+20) at day 2. aindicates p ≤ 0.08, * indicates p ≤ 0.05, ** indicates p ≤ 0.001.   
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5.6.4 Motivation and the Placebo Effect in Nausea 
The BIS/BAS was included in the present study to investigate negative (BIS) as well as 
positive (BAS) aspects of motivation on the placebo effect. Therefore, sum of BIS and BAS 
scores were correlated with the placebo effect (spontanous changes from day 1 to day 2 in the 
control group, respectively) on expected and perceived nausea, perceived motion sickness, 
perceived stress at t = +10 and +20, cortisol, amylase, and delta power, spereately for the control 
and the placebo subjects (Tables 14 and 15).  
Table 14. Correlations across control subjects separately for the BIS and the BAS with 
spontaneous changes on expected and perceived nausea, perceived stress, cortisol, amylase, and 
delta power 
 
Note. Spontaneous changes were defined as the baseline corrected mean values at day 1 minus the baseline cor-
rected mean values at day 2 in the listed variables: Expected nausea at t=+10, perceived nausea as the average over 
t = +10 to t = +20, perceived stress at t = +10 and t = +20, logarithmized (ln) cortisol levels at t = +35, ln amylase 
levels at t=+20, percentage of delta power of the total FFT (fast Fourier transformed) spectrum in electrode C3, 
percentage of delta power of the total FFT spectrum in electrode C4. BAS: Behavioral approach system scale. BIS: 




Table 15. Correlations across placebo subjects separately for the BIS and the BAS with 
placebo effects on expected and perceived nausea, perceived MS, perceived stress, cortisol, 








Note. Placebo effects were defined as the baseline corrected mean values at day 1 minus the baseline corrected 
mean values at day 2 in the listed variables: Expected nausea at t=+10, perceived nausea as the average over t = 
+10 to t = +20, perceived stress at t = +10 and t = +20, logarithmized (ln) cortisol levels at t = +35, ln amylase 
levels at t=+20, percentage of delta power of the total FFT (fast Fourier transformed) spectrum in electrode C3, 
percentage of delta power of the total FFT spectrum in electrode C4. BAS: Behavioural approach system scale. 
BIS: behavioural inhibition scale. a indicates trend towards significant correlation p ≤ .08, * indicates p ≤ .05, ** 
indicates p ≤ .001. 
In the control group, mean BAS values were positively associated with the magnitude of 
spontaneous decrease from day 1 to day 2 in: (a) perceived stress at t = +10 (rs(16) = 0.61, 
p=0.01), and (b) delta power in C4 (rs(19) = -0.48, p=0.04; Figure 12: H).  
 In the placebo group, BAS scores were negatively associated with the placebo effect on: 
(a) perceived stress at t = +20 (rs(42) = -0.36, p=0.02), and (b) delta power in C3 and C4 (C3: 
rs(42) = 0.46, p=0.00; C4: rs(42) = 0.46, p=0.00; Figure 12: I).   




Figure 12. Scatterplots H: Positive correlation in the placebo group between the total BAS 
scores and the placebo effect on G) delta power in C4. Scatterplot I: Negative correlation in the 
control group between the total BAS scores and the spontaneous changes in delta power in C4. 
* indicates p ≤ .05, ** indicates p ≤ .001.   
5.7 Exact Low Resolution Brain Electromagnetic Tomography 
5.7.1 Acute Nausea  
eLORETA analysis revealed no significant group differences in baseline recordings, nei-
ther on day 1 nor on day 2 (all p ≥ 0.05). This was important to ensure meaningful comparison 
of nausea and placebo-related changes between groups. During acute nausea at day 1, nausea-
related changes compared to the baseline recordings were shown in the following areas (ex-
treme p = 0.00, t = 7.49, Table 16, Figure 13): the limbic, parietal, occipital, temporal, frontal 





Table 16. Coordinates for brain areas showing significant differences between acute nau-
sea and baseline at day 1 in MNI current density across all participants  
 
Note. Current density during acute nausea was computed from EEG (electroencephalography) recordings over t = 
+10 to +20, baseline current density from EEG over t = -20 to -10 at day 1. MNI: Montreal Neurological Institute. 













Figure 13. Comparison of acute nausea (mean over t = +10 to t = +20) and baseline (mean over 
t = -20 to t = -10) at day 1 across both sexes. The color bar represents t-statistic with t ≥ 3.52 
(two-tailed) indicating p ≤ 0.05. Source: Montreal Neurological Institute coordinate system 
(MNI). 
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5.7.1.1 Gender Effects on Acute Nausea  
In order to reveal sex specific cortical mechanism underlying nausea, acute nausea was 
compared to baseline at day 1, separately for male and female. The following significant nau-
sea-related changes emerged in the female group (extreme p = 0.00, t = 5.24, Table 17): alpha 
and beta I activity in the limbic, parietal, occipital, tempo lobe, and insula. Similar nausea-
related changes emerged in the male group (extreme p = 0.00, t = 6.44, Table 18): alpha and 
beta activity changes in the limbic, parietal, occipital, temporal, frontal lobe, and the insula. 
This may indicate that during acute nausea, similar brain regions are active in males and fe-
males.  
Table 17. Coordinates for brain areas showing significant differences between acute nau-
sea and baseline at day 1 in MNI current density across female subjects 
 
Note. Current density during acute nausea was computed from EEG (electroencephalography) recordings over t = 
+10 to +20, baseline current density from EEG over t = -20 to -10 at day 1. MNI: Montreal Neurological Institute. 





Table 18. Coordinates for brain areas showing significant differences between acute nau-
sea and baseline at day 1 in MNI current density across male subjects 
 
Note. Current density during acute nausea was computed from EEG (electroencephalography) recordings over t = 
+10 to +20, baseline current density from EEG over t = -20 to -10 at day 1. MNI: Montreal Neurological Institute. 
All t-values ≥ 3.59 indicate p-values ≤ 0.05. 
5.7.2 Expectancy  
In line with the main hypothesis on the source localization analysis, a placebo related 
decrease was shown at day 2 (anticipatory period, measured during t = -10 to 0, the time period 
following expectancy manipulation) in delta (0.5 - 4 Hz) activation arising from peak voxels in 
the frontal and anterior cingulate cortex (extreme p ≤ 0.001, t ≥ 3.63, Table 19, Figure 14), as 
well as decreased theta (4.1 - 8) oscillations arising from peak voxels in the frontal lobe. Con-
trastingly, in the control group, no significant differences between the recordings during base-
line and after the randomization at day 2 emerged (p ≥ 0.05). When stratifying by gender, no 
significant effects in the placebo groups during the anticipation phase emerged (p ≥ 0.05).  
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Table 19. Coordinates for brain areas showing significant differences following expec-
tancy manipulation compared to baseline at day 2 in the placebo group 
 
Note. Current density during anticipation phase (following expectancy manipulation) was computed from EEG 
(electroencephalography) recordings over t = -10 to 0, baseline current density from EEG over t = -20 to -10 at 
day 2. MNI: Montreal Neurological Institute. All t-values ≥ 3.63 indicate p-values ≤ 0.05. 
 
Figure 14. Comparison of the anticipation phase following expectancy manipulation (mean 
over t = -10 to t = 0) and baseline (mean over t = -20 to t = -10) at day 2 for the placebo group 
including both sexes. The color bar represents t statistic with t ≥ 3.63 (two-tailed) indicating p 
≤ 0.05. Source: Montreal Neurological Institute coordinate system (MNI). 
5.7.3 Placebo Effect on Nausea 
To reveal placebo-related effects following sham acupuncture, acute nausea at day 2 was 
compared to acute nausea at day 1, separately for the placebo and the control group. No signif-
icant effects emerged in the control group (all p ≥ 0.05), not even if stratified by gender (in 




Although, no placebo-related changes were found in the placebo group across both sexes, 
when stratifying by gender, placebo related activation in females (extreme p ≤ 0.02, t = 4.04, 
Table 20, Figure 15) and males (extreme p ≤ 0.03, t = -3.78, Table 21, Figure 16) emerged. 
Specifically, the female placebo group showed changes in alpha and beta activation from peak 
voxels in parietal, temporal, and frontal lobe. In the male placebo group, there was a change in 
alpha activation in the limbic lobe and the insula.  
Table 20. Coordinates for brain areas showing significant differences in MNI current 
density during acute nausea following placebo intervention at day 2two compared to acute 
nausea at day 1 in the female placebo group 
 
Note. Current density during acute nausea was computed from EEG (electroencephalography) recordings over t = 
+10 to +20 at day 1 and day 2. MNI: Montreal Neurological Institute. All t-values ≥ 3.98 indicate p-values ≤ .05. 
Table 21. Coordinates for brain areas showing significant differences in MNI current den-
sity during acute nausea following placebo intervention at day 2 compared to acute nausea at 
day 2 in the male placebo group. 
 
Note. Current density during acute nausea was computed from EEG (electroencephalography) recordings over t = 
+10 to +20 at day 1 and day 2. MNI: Montreal Neurological Institute. All t-values ≥ -3.54 indicate p-values ≤ 0.05.   




Figure 15. Comparison of acute nausea at day 1 (mean over t = +10 to +20) and acute nausea 
at day 2 (mean over t=+10 to +20) in the female placebo group. The color bar represents t-
statistic with t ≥ 3.98 (two-tailed) indicating p ≤ 0.05. Source: Montreal Neurological Institute 













Figure 16. Comparison of acute nausea at day 1 (mean over t = +10 to +20) and acute nausea 
at day 2 (mean over t = +10 to +20) in the male placebo group. The color bar represents t-
statistic with t ≥ -3.57 (one-tailed) indicating p ≤ 0.05. Source: Montreal Neurological Institute 





Nausea is a debilitating side effect that can seriously impair daily functioning in numerous 
populations (e.g. chemotherapy patients, pregnant women, car drivers/passengers etc.). Unfor-
tunately, most treatments fail to alleviate nausea in these populations. However, nausea has 
been shown to be sensitive to placebo interventions. The present study was designed to achieve 
a better understanding of the placebo effect (psychosocial factors) in nausea and its underlying 
neurobiological mechanisms. To this end, placebo effects in nausea in relation to stress hor-
mones and altered brain activity were studied. This investigation was crucial because it is as-
sumed that neurobiological mechanisms underlying nausea may explain why nausea is sensitive 
to placebo interventions and therefore yield powerful implications to the treatment of nausea. 
6.1 Main Findings 
The research results emphasize the robustness of sham acupuncture in combination with 
verbal instruction to elicit placebo effects in nausea, as it clearly reduced expected and per-
ceived nausea in both sexes, on a behavioral, cortical, and hormonal level.  Specifically, the 
following three main findings in respect of the study hypothesis and sex differences emerged: 
The verbal placebo instruction successfully reduced expected nausea on the NRS com-
pared to the no-treatment group. On a cortical level, this effect was accompanied by changes in 
PFC and ACC activity in both sexes. 
The placebo intervention significantly alleviated acute nausea on the NRS compared to 
the no-treatment group. The cortical correlates of the placebo effect on nausea differed for males 
and females: in males, the placebo effect on nausea displayed changes in the limbic, sub-lobar, 
and occipital lobe. In females, the placebo effect was accompanied by reduced delta power in 
the FFT spectrum and changes in parietal, frontal, and temporal lobe.  
The placebo intervention elicited the intended effect in reducing stress exclusively in the 
female placebo group, which was indexed on a cortical and a hormonal level: females who 
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experienced a lower level of stress also showed greater placebo effects on nausea and delta 
power in C4 relative to subjects who stayed relatively stressed during acute nausea. Further-
more, the placebo-induced stress reduction was indexed by reduced amylase levels (which in-
dicate a decrease in SNS activity) and amylase in turn was associated with the placebo effect 
on perceived nausea and delta power. Hence, stress, delta power, and amylase seem to modulate 
the placebo effect in nausea in females. In contrast, the stress levels in males remained unaf-
fected by the placebo intervention, that is to say, there was a spontaneous stress reduction from 
day 1 to day 2 in both male groups.  
In summary, these data indicate the effectiveness of sham acupuncture in nausea and 
shows that cortical mechanisms are involved in females and males. In particular, the positive 
expectation of nausea improvement following verbal instruction seems to be similarly modu-
lated in females and males, specifically via PFC and ACC. On the other hand, the placebo effect 
on nausea itself may be differentially modified in females and males. Different cortical areas 
were found to be active during the placebo effect in nausea for females and males and placebo-
induced reductions in stress, delta power, and amylase were only observed in females.    
6.2 Critical Evaluation  
Certain limitations of the present study design and its measurements should be acknowl-
edged. Firstly, the present analyses focuses on 90 participants, which was split into two groups 
(30 control and 60 placebo participants). The mismatch between group sizes was due to an 
initial hypothesis that somatosensory stimulation  (tingling in 30 enhanced placebo subjects) 
compared to no somatosensory stimulation (in 30 simple placebo subjects) at the sham acu-
puncture points would enhance the placebo effect on nausea. As preliminary analysis indicated 
no significant differences between simple placebo and enhanced placebo, both placebo groups 
were combined to increase the efficiency of all present results. In other words, the sample size 




of type II errors for the findings in the control group. Furthermore, even though there were no 
significant differences on a behavioral and bodily level between the two placebo groups; it is 
possible that the somatosensory stimulation in the enhanced placebo group could have influ-
enced cortical processes not detected by the present study.  
Secondly, there was an overall stress reduction in men from day 1 to day 2, which may 
have hindered the detection of differences in placebo-induced stress reductions between the 
male placebo and control groups. This should be taken into account when discussing the finding 
that stress was exclusively reduced during acute nausea at day 2 in the female placebo group.  
Thirdly, the spacial resolution of EEG is less reliable compared to fMRI recordings and 
may have failed to reveal nausea or placebo-relevant brain structures, most prominently the 
absence of ACC activity during acute nausea at day 1 (see section 6.3.1). Also, one should take 
into account that more activation in the EEG does not automatically mean more activation in 
certain areas or vice versa. An increase in current density (LORETA) or spectral power (FFT) 
can also reflect electron inhibition.   
6.3 Discussion of the Main Findings 
6.3.1 Nausea Induction  
The implemented nausea induction across all subjects at day 1 allowed to control behav-
ioral, cortical, and hormonal correlates - naturally triggered by the vection drum. The following 
results are important in order to understand placebo-related changes. The subjective nausea 
response at day 1 was accompanied by elevated stress, accompanied by increased cortisol levels 
and delta power (0.5-4 Hz). This replicates previous findings that increased delta power above 
central cortical electrodes (Hu et al., 1999) and stress are involved in acute nausea (Levine, 
2017). Additionally, the present study allowed for a deeper investigation into the relation be-
tween delta power and nausea due to the addition of stress relevant parameters, important pa-
rameters which have been absent in previous studies.  
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Furthermore, correlation analysis revealed that the increase in delta power did not directly 
correlate with the elevated nausea experience as reported in previous studies (Hu et al., 1999). 
In contrast, nausea positively correlated with an increase in stress and cortisol. In turn, cortisol 
positively correlated with the magnitude of stress and the increase in delta power.  Therefore, 
the increase in delta power may reflect changes in stress-relevant brain areas underlying nausea 
rather than the direct nausea-related brain activity.  
Furthermore, source-level analyses revealed nausea-related changes in the limbic, parie-
tal, occipital, and PFC as well as in the insula. All these areas were previously found to be 
involved in nausea in the context of motion sickness (Chelen et al., 1993; Chen et al., 2010; 
Farmer et al., 2015; Hu et al., 1999; Ko et al., 2011; Napadow et al., 2013). On the other hand, 
some areas that have also been shown to be involved in nausea were not detected in the present 
study: the motor (Ko et al., 2011), orbitofrontal, somatosensory area and the ACC (Napadow et 
al., 2013). Specifically, the absence of the ACC is in contrast to Farmer (2015) and Napadow 
(2013) who suggested that the ACC strongly interacts with the PFC and together act as key 
components in the development of nausea. One explanation for this discrepancy could be that 
the induction of nausea was implemented differently and the source localization was based on 
fMRI recordings instead of EEG. Farmer (2015) and Napadow (2013) induced nausea within 
the fMRI scanner via special goggles and Farmer used a different video to induce illusory mo-
tion, with real pictures instead of alternating black and white stripes. Regarding the measure-
ment, fMRI detects the level of oxygen in the blood and allows a higher level of local resolution 
compared to EEG, which records the average of voltage (electrical potentials) at the scalp. Elec-
trical potentials have a higher temporal resolution than fMRI signals but in order to define local 
brain activity, they have to be traced back to their source within the brain, which is based on 
estimation analysis. Since no other EEG study has revealed the ACC while contrastingly, all 




nausea in the present study but was not significant because of the limited local resolution of 
EEG compared to fMRI.  
Taken together, this analysis on nausea, cortisol, stress, and delta power at day 1 showed 
that participants who are relatively stressed also showed increased cortisol levels and increased 
nausea. Additionally, higher stress levels were accompanied by increased delta power in C3 and 
several nausea-related brain areas were revealed, such as the PFC. Again, the PFC is crucial in 
stress regulation and the increase in delta power directly correlated with stress. Hence, the pre-
sent data may indicate cortisol and delta power as potential physiological stress modulators in 
nausea and strengthens the assumption that nausea-related brain areas overlap with cortical 
stress components (Levine, 2017; Toschi et al., 2017). 
6.3.2 Expectancy Manipulation 
Both sexes showed reduced expectation of nausea following verbal placebo instruction 
and sham acupuncture on the NRS. This was accompanied by changes in PFC and ACC, which 
may index the placebo-related modulation of the mind towards a positive treatment outcome. 
This assumption is reasonable, especially for the PFC activity, in light of the many previous 
placebo studies which have shown that the PFC is key area during placebo instruction effects 
(Benedetti, 2010; Hunter et al., 2006). In placebo anxiolysis, which reflects the reduction of 
fear and anxiety following placebo treatment, changes in frontal activity and ACC were also 
detected, and positive expectation towards the placebo treatment and ACC activity directly cor-
related with the subjective placebo effect (Meyer et al., 2015; Petrovic et al., 2005). The authors 
suggest that subjects recruit frontally based cognitive control functions during an expectancy 
manipulation that diminishes feelings of unpleasantness. The present findings are in line with 
these assumptions, even though anxiety and fear were not explicitly controlled, though they are 
closely linked to stress, which was reduced during acute nausea in the female placebo group.   
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6.3.3 Placebo Effect on Nausea 
The placebo intervention elicited the intended effect of reducing nausea on a behavioral, 
cortical, and hormonal level (though the latter was only true in females). This is in line with the 
pilot study by Müller and colleagues (2016). Additionally, in this study the placebo intervention 
was also successfully tested in males (even without somatosensory stimulation at the electrodes 
site of the placebo TENS device) and found no sex differences on the placebo effect in nausea 
on a behavioral level. In contrast, the bodily correlates of the placebo response in nausea dif-
fered between males and females: in males, the placebo effect on nausea displayed changes in 
the limbic, sub-lobar, and occipital lobe. In females, on the other hand, the placebo effect was 
accompanied by reduced delta power in parietal, frontal, and temporal regions.  
This pattern fits with placebo research in other domains, where gender does not appear to 
have a significant influence on the placebo response on the behavioral level (in placebo anal-
gesia: Averbuch & Katzper, 2001; Weimer, Colloca, & Enck, 2015; in depression: Casper, 
Tollefson, & Nilsson, 2001), but instead plays a larger modulatory role on the cortical 
(Aslaksen, Bystad, Vambheim, & Flaten, 2011) and hormonal level (Colloca, Pine, Ernst, Mil-
ler, & Grillon, 2016). Specifically, vasopressin agonists enhanced the placebo response in 
women but not in men (Colloca et al., 2016). In contrast, in the study by Aslaksen and col-
leagues (2011) only men displayed a placebo response in N2/P2 ERP. Such discrepancies show 
the importance of controlling for gender effects, especially when investigating bodily corre-
lates.  
One possible explanation for the gender effects in the present study may be that the pla-
cebo response in females was more strongly modulated through a down-regulation of stress. 
This assumption is plausible, based on the finding that there was a placebo-induced stress re-
duction during acute nausea on the NRS only in females. The present study cannot clarify to 




(Levine, 2017) and no regression analysis was run, but the placebo effect in females was ac-
companied by changes in delta power, PFC activity, and amylase levels. All these correlates 
have been linked to stress in previous studies (Hall et al., 2007; Nater et al., 2006; McEwen et 
al., 2015). Specifically, delta power was found to index nausea-induced stress at day 1 in the 
present study. Additionally, PFC activity could be associated with nausea related changes in the 
ANS (Napadow et al., 2013; Toschi et al., 2017) and the ANS response of stress and nausea 
showed similar pattern (Levine, 2017). In summary, the present data supports the idea that not 
only the ANS response but also the cortical circuitry underlying nausea is closely linked to 
stress and is modifiable via placebo interventions in females. 
Furthermore, it was hypothesized that the placebo-induced reduction in stress would be 
indexed by decreased cortisol levels; this turned out not to be the case. Cortisol was linked to 
stress, delta power, and nausea at day 1 but not to the behavioral placebo response, neither in 
females nor in males. At first glance, this seems surprising because females did show a placebo-
induced stress reduction during acute nausea and cortisol robustly indexes stress (Lovallo & 
Thomas, 2000) yet, on the other hand, a previous study detected the very same pattern of corti-
sol in placebo analgesia (Johansen, Brox, & Flaten, 2003). They investigated cortisol in three 
groups: a no-treatment group, a placebo group, and a nocebo group. Pain was significantly 
reduced in the placebo group following sham intervention compared to the other groups but 
changes in cortisol did not correlate with placebo analgesia (increased cortisol levels were ob-
served in all three groups, with the most significant rise in the nocebo group). In summary, 
cortisol might play a critical role in nausea-related stress but does not modulate the actual pla-
cebo response in nausea. Since amylase levels were associated with the placebo response on 
nausea in females, future studies may include amylase to reveal hidden placebo-induced stress 
mechanisms. 




It was hypothesized that positive aspects of motivation (BAS) were related to the behav-
ioral placebo response in nausea. Although BAS scores did not correlate with the placebo effect 
on NRS nausea, BAS scores positively correlated with the magnitude of the placebo effect on 
delta power in both electrodes (C3 and C4). In the control group it was the other way around, 
here BAS scores correlated negatively with the spontaneous changes in delta power from day 
1 to day 2. In placebo analgesia, reward-related brain activity predicted the placebo analgesic 
response, specifically within the ACC and the PFC (Schweinhardt, Seminowicz, Jaeger, Dun-
can, & Bushnell, 2009). Notably, the present study revealed placebo-related activity in the PFC 
and the ACC during the anticipation phase following expectancy manipulation, which emerged 
within the delta spectrum. Hence, the present data suggests that delta power in nausea is not 
only linked to nausea-related stress but also to higher cortical functions such as motivation (or 
in this case, to the anticipation of reward which was the positive treatment outcome - nausea 
reduction). 
Furthermore, the BAS scores correlated negatively with the placebo effect on stress and 
positively with the spontaneous changes in stress from day 1 to day 2 in the control group. Even 
though no specific hypotheses were formulated for motivation in relation to stress, it is surpris-
ing that the BAS correlated negatively with the placebo effect on stress.  We would rather have 
expected to find the opposite: that positive aspects of motivation would increase placebo-in-
duced stress reductions (de la Fuente-Fernández, Schulzer, & Stoessl, 2004). On the other hand, 
a previous study that investigated the BIS/BAS in relation to the placebo effect on stress dis-
played the very same inverse pattern (Darragh, Booth, & Consedine, 2014). Lower BAS scores 
predicted higher placebo effects on stress and the opposite was found in the control group. The 
authors suggested that different contextual contingencies activate different behavior so that sim-




findings support this view as the randomization of subjects into control and placebo groups 
imposed different requirements on the subjects, such that highly motivated subjects may have 
habituated more quickly to the nausea induction and therefore experienced less overall stress at 
day 2. In contrast, high motivated subjects in the placebo group may have experienced higher 
levels of arousal (stress) at day 2 compared to day 1 because the sham acupuncture was novel 
and, as a result, benefitted more from the placebo intervention.   
6.4 Summary and Conclusions  
By now, it is clear that the psychosocial context of administering medication can influence 
neurobiological mechanism. Researchers have increasingly suggested that the placebo effect is 
mainly modulated via positive expectations towards a treatment, mediated by PFC and ACC 
activity, which seem to be additionally linked to motivational aspects (reward-based mecha-
nism). Once positive expectations are induced, the ‘inner doctor’ acts specifically on the bodily 
correlates, depending on the relevant condition. The present study was successful in showing 
evidence for both assumptions in a nausea model. Firstly, the placebo intervention significantly 
reduced expected nausea in the placebo group compared to the control group during the antici-
pation phase and this was accompanied by changes in PFC and ACC activity within the delta 
spectrum. Secondly, the actual placebo response during nausea induction was accompanied by 
blunted stress levels (in females only), changes in amylase (in females only), decrease in delta 
power (in females only), and changes in nausea-related brain areas (this also was sex specific).  
The German Medical Association claims that the placebo effect should be implemented 
in clinical practice but that domain specific evidence is needed for each to facilitate its applica-
tion (Kupferschmidt, 2011). The present study was able to replicate that the placebo effect plays 
a significant role in nausea, in both men and women, and provided empirical evidence that it 
interrelates with underlying neurobiological mechanisms.  
The placebo effect in the present study was induced by means of a positive and convincing 
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verbal instruction towards the placebo treatment and therefore reduced ‘fearful’ expectations of 
developing nausea. This strengthens the suggestion that treatments of nausea should more seri-
ously focus on psychological aspects to reduce anticipatory nausea, for example reducing high 
initial expectations of nausea in cancer patients before receiving chemotherapy (Colagiuri & 
Zachariae, 2010). 
In a way, the present study also contributed to the mind-body interaction debate as it 
clearly showed that the subjective experience of nausea was accompanied by neurobiological 
changes. Specifically, it was shown that during the anticipation phase - in which nothing else 
was manipulated but the mind - subjective expectation changed in the placebo participants, 
indexed by altered PFC and ACC activity. Hence, body and mind should never been treated in 
separation, but instead should be integrated and seen as important elements in health care.   
6.5 Outlook 
Future investigations may control more thoroughly for the impact of psychosocial factors 
(e.g. fear, unpleasant feelings, and tension) in nausea and the placebo effect for a better course 
in the treatment of nausea. For example, Quinn and colleagues (2015) just recently induced a 
method that allows for the study of nocebo effects on nausea. The method is called galvanic 
vestibular stimulation (GVS; Quinn, MacDougall, & Colagiuri, 2015; Quinn & Colagiuri, 
2016). GVS works with electrical stimulation and also includes a sham stimulation program 
that induces a nocebo effect on nausea. One advantage of this method is that the sham GVS and 
the active GVS are difficult to distinguish because they both induce tingling at the electrodes 
site. One idea would be to study the sham GVS in comparison with the active GVS within the 
fMRI. This would allow to distinguish the psychosocial components (nocebo nausea induced 
by the sham GVS) from the pure bodily components (active GVS minus sham GVS). 
 Finally, cortisol was not affected by the placebo intervention but was indeed involved 




Benedetti and colleagues (2003) detected placebo-induced hormonal changes only in response 
to conditioning not to expectancy manipulation, it is possible that cortisol is only involved in 
conditioning induced placebo effects in nausea. Hence, it will be of interest to study in more 
detail the role of cortisol in the placebo effect in nausea by conditioning.  
In conclusion, more detailed insights about the exact psychosocial factors that modulate 
the development of nausea should be addressed. In particular, the exact influence of stress in 
comparison to fearful expectations. This will yield important implications to the treatment of 
nausea, especially because physicians can easily be trained to trigger the relevant psychosocial 
components.  




Background. Evidence indicates that nausea can be modulated by placebo interventions, 
however, little is known about the underlying cognitive mechanisms. Therefore, the present 
study examined behavioral and electroencephalography (EEG) correlates of the placebo effect 
on nausea.  
Methods. On two consecutive days, 90 healthy subjects (45 females) were exposed to a 
nauseating visual stimulus for 20 minutes. Nausea was continuously rated on a numeric rating 
scale (a ‘10’-point NRS, with ‘0’ indicating no nausea and ‘10’ maximal tolerable nausea). Day 
1 served as a control condition. Placebo intervention occurred during day 2. Subjects were split 
into two groups: the placebo group received sham acupuncture (coupled with expectancy ma-
nipulation of nausea improvement), whereas subjects in the control group did not receive any 
treatment. Thirty-two channels of EEG were recorded during baseline and nausea exposure on 
both days as well as during the placebo intervention on day 2. Fast Fourier transformation (FFT) 
at central electrodes C3 and C4 and exact low resolution electromagnetic tomography 
(eLORETA) were used to examine EEG correlates of the placebo effect in nausea. 
Results. On the first day, both sexes showed severe nausea (NRS ≥ 5) in response to the 
nauseating stimulus. The nausea response was associated with elevated delta power (0.5-4 Hz) 
in the FFT spectrum. Additionally, source-level analyses revealed nausea related changes in the 
limbic, parietal, occipital, and frontal lobe, as well as in the insula. On day 2, both sexes showed 
reduced expectation of nausea following expectancy manipulation and sham acupuncture point 
stimulation on the NRS, indexed by changes in frontal lobe and anterior cingulate activity. In 
line with the main hypothesis in this study, both sexes showed a placebo effect on nausea, in-
dexed by reduced nausea on the NRS. Among females, the placebo effect was accompanied by 
reduced delta power in the FFT spectrum, decreased placebo related activation in parietal, 




nausea in males displayed increased activation in the limbic, sub-lobar, and occipital lobe.  
Conclusion. Results emphasize the effectiveness of sham acupuncture in nausea and al-
low first insights into underlying central mechanisms in females and males. In particular, the 
positive expectation of nausea improvement following expectancy manipulation and sham ac-
upuncture seems to be similarly modulated in females and males, specifically via frontal struc-
tures. On the other hand, the placebo effect on nausea alone may be differentially modified in 
females and males in the central nervous system.   
Keywords: placebo effect, nausea, stress, motivation, electroencephalography 
 
  




Hintergrund. Bisher konnten zahlreiche Studien Placeboeffekte im Bereich Übelkeit 
nachweisen, zugrundeliegende neurokognitive Mechanismen sind jedoch weitgehend unklar.  
Im Rahmen dieses Projektes wurden verhaltensbezogene und elektroenzephalografische (EEG) 
Korrelate der Placeboantwort in einem Übelkeitsparadigma untersucht.  
Methodik. An zwei aufeinanderfolgenden Tagen (Tag 1 und Tag 2) wurde Übelkeit in 
90 gesunde Probanden (45 Frauen) über 20 Minuten lang mithilfe eines visuellen Stimulus er-
zeugt. Tag 1 diente als Kontrolltag. An Tag 2 wurden die Probanden in die Kontrollgruppe be-
ziehungsweise in die Placebo Gruppe eingeteilt. Die Placebo Gruppe erhielt Scheinakupunktur 
in Kombination mit einer positiven Erwartungsmanipulation. In der Kontrollgruppe wurde 
keine Intervention angewandt. Verhaltensbezogene Übelkeit wurde auf einer Numerischen Ra-
ting Skala (‚10‘-Punkte NRS, ‚0‘ entsprach keiner Übelkeit und ‚10‘ maximal tolerierbarer 
Übelkeit) und EEG mit 32 Elektroden kontinuierlich an beiden Tagen gemessen.  Fast-Fourier 
Transformation (FFT) in den Elektroden C3 und C4 und exact Low Resolution Electromagnetic 
Tomography (eLORETA) wurden verwendet, um neurokognitiven Korrelate der Placeboant-
wort auf Übelkeit aufzuzeigen.  
Ergebnisse. An Tag 1 zeigten beide Geschlechter signifikante Übelkeit (NRS ≥ 5) als 
Reaktion auf den visuellen Übelkeitsstimulus. Behaviorale Übelkeit wurde begleitet von erhöh-
ter Delta Aktivität (0.5-4 Hz) im FFT Spektrum sowie veränderter Aktivität in limbischen, pa-
rietalen, okzipitalen und frontalen Hirnregionen und der Inselrinde.  An Tag 2 zeigten beide 
Geschlechter in der Placebo Gruppe eine Reduzierung der erwarteten Übelkeit auf der NRS und 
Veränderungen im frontalen und anterioren cingulären Cortex im Vergleich zur Kontrollgruppe. 
Ebenso zeigten beide Geschlechter in der Placebogruppe eine signifikante Reduzierung der 




war die Placeboantwort begleitet von einer reduzierten Delta Aktivität im FFT Spektrum, redu-
zierter Aktivität in parietalen, frontalen und temporalen Hirnregionen sowie reduziertem sub-
jektiven Stress. Im Gegensatz dazu ging die Placeboantwort auf Übelkeit bei Männern mit er-
höhter Aktivität in limbischen und okzipitalen Hirnregionen einher.  
Schlussfolgerung. Die vorliegenden Ergebnisse zeigen, dass Scheinakupunktur in 
Kombination mit einer positiven Erwartungsmanipulation erfolgreich eine Placeboantwort im 
Bereich Übelkeit bei beiden Geschlechtern induzieren konnte und erlauben erste Einblicke in 
die zugrundeliegenden neurobiologischen Korrelate. Speziell die positive Erwartungsmanipu-
lation ging gleichermaßen für Männer und Frauen mit neurobiologischen Veränderungen im 
frontalen und anterioren cingulären Kortex einher. Im Gegensatz dazu, vielen die neurobiolo-
gischen Korrelate der Placeboantwort auf Übelkeit für Männer und Frauen unterschiedlich aus.  
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